ABANDONED - NO STATEMENT OF USE FILED
no statement of use filed
on 09 Sep 2024
Last Applicant/ Owned by
400 Oyster Point Boulevard, Suite 505
South San Francisco
CA
94080
Serial Number
87457505 filed on 19th May 2017
Registration Number
N/A
Correspondent Address
Muzamil Huq
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
TITAN PHARMACEUTICALS
Pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune syst Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 87457505
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 304146014002
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 09th Sep 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| 09th Sep 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| 30th Jan 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 28th Jan 2024 | SOU EXTENSION 3 GRANTED |
| 28th Jan 2024 | SOU EXTENSION 3 FILED |
| 28th Jan 2024 | SOU TEAS EXTENSION RECEIVED |
| 27th Dec 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 27th Dec 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 27th Dec 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 19th Jul 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |